Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Endometrial01: T-DXd + Rilvegostomig or Pembrolizumab vs Chemotherapy + Pembrolizumab in 1L HER2-Expressing Endometrial Cancer
NCT06989112Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2025
- Primary completion
- Jan 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 23
01
Overview
A Phase 3 trial of trastuzumab deruxtecan, rilvegostomig in endometrial cancer (EC), sponsored by AstraZeneca. Started Mar 2025; status: recruiting.
02
Drugs
trastuzumab deruxtecanrilvegostomig
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06989112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06989112.